Because people that carry the APOE e4 gene variant show up to possess a bigger risk of serious issues, the FDA suggests currently being tested for that gene variant before beginning treatment with lecanemab or donanemab. About pharmacological interventions, three guidelines suggest no pharmacologic intervention. Using cholinesterase inhibitors for MCI https://zanerjuwg.bleepblogs.com/34868641/dementia-testing-near-me-fundamentals-explained